In 2005 Kurzweil named the decade, the substrate, and the architecture. In 2024 he quietly moved every date ten years. But the deeper question is whether ‘nanobot’ was the wrong word all along — and CRISPR, base editors, and LNPs are fulfilling the original vision in a body Kurzweil didn’t name.
Seven approved RNAi drugs, one CRISPR medicine for sickle cell, and a stem-cell cure inching toward filing — but every one arrived through mechanisms Kurzweil did not forecast in 2005.
Twenty-one years after Singularity Is Near, ten claims Kurzweil said were already true: what held up, what got overtaken, and the company whose path he rewrote.